Fibromyalgia (FM) is a chronic pain condition characterized by diffuse and persistent non-inflammatory musculoskeletal pain. It is estimated that the prevalence of FM in the general population ranges from 2-4%, with it being more frequently diagnosed in women compared to men (Galvez-Sánchez & Reyes del Paso, 2020).
The percentage of Americans who "believe the (m)ajority of (v)eterans (e)xperience PTSD," according to a recent America’s Mental Health PTSD Pulse Survey conducted by the Cohen Veterans Network.
As we close out this year's PTSD Awareness Month, we wanted to take a quick look at some of the many resources that the CDP and other organizations have compiled to help further the effort.
It’s tough to keep up with the “latest and greatest” interventions for Post-Traumatic Stress Disorder (PTSD). It seems like there’s constantly a new “breakthrough” that never fully delivers. As a scientist-practitioner, I don’t pay much attention until I see a strong research base. So until recently, I’ve all but ignored claims that psychedelic drugs (MDMA, psilocybin, etc.) could bolster recovery from PTSD. However, it’s tough to ignore the successes reported in a recent Phase 3 trial.
Based on clinical experience, training and supervision, and findings from the literature, Dr. Rogers explores various issues related to the diagnosis of and diagnosing PTSD in this blog. During this month devoted to awareness of PTSD, it is appropriate to take time focus on the diagnosis and the practice of diagnosing PTSD.